

NONTHAVEJ HOSPITAL PUBLIC COMPANY LIMITED

FINANCIAL STATEMENTS

DECEMBER 31, 2023

518/3 อาคารเมธียาเซ็นเตอร์ นอช ชั้น 7
ถนนเพลินจิต แขวงลุมพินี
เขตปทุมวัน กรุงเทพฯ 10330
โทร./โทรสาร 0-2255-2518
0-2250-0634
0-2254-8387
โทรสาร อัดโนมัติ 0-2253-8730
อีเมล virach5183@yahoo.com
เว็บไซต์ http://www.vaaudit.com

V & A

บริษัท สำนักงาน ดร.วิรัช แอนด์ แอสโซซิเอตส์ จำกัด
DR.VIRACH & ASSOCIATES OFFICE CO., LTD.

CERTIFIED PUBLIC ACCOUNTANTS
สำนักงานใหญ่ เลขประจำตัวผู้เสียภาษี 0105556000751

518/3 Maneeya Center North Building
7th Floor, Ploenchit Road, Lumpinee District
Khet Patumwan, Bangkok 10330
Tel./Fax 66 (0) 2255-2518
2250-0634
2254-8387
Auto Fax 66 (0) 2253-8730
Email virach5183@yahoo.com
Website http://www.vaaudit.com

AUDITOR'S REPORT

To : The Shareholders of

Nonthavej Hospital Public Company Limited

Opinion

I have audited the accompanying financial statements of Nonthavej Hospital Public Company Limited, which comprise the statements of financial position as at December 31, 2023, the related statements of comprehensive income, changes in shareholders' equity and cash flows for the year then ended, notes to the financial statements, including a summary of significant accounting policies.

In my opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Nonthavej Hospital Public Company Limited as at December 31, 2023, its financial performance and cash flows for the year then ended, in accordance with Thai Financial Reporting Standards.

Basis for Opinion

I conducted my audit in accordance with Thai Standards on Auditing. My responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of my report. I am independent of the Company in accordance with the Code of Ethics for Professional Accountants including Independence Standards issued by the Federation of Accounting Professions (Code of Ethics for Professional Accountants) that are relevant to my audit of the financial statements, and I have fulfilled my other ethical responsibilities in accordance with the Code of Ethics for Professional Accountants. I believe that the audit evidence I have obtained is sufficient and appropriate to provide a basis for my opinion.

Key Audit Matters

Key audit matters are those matters that, in my professional judgment, were of most significance in my audit of the financial statements of the current period. These matters were addressed in the context of my audit of the financial statements as a whole, and in forming my opinion thereon, and I do not provide a separate opinion on these matters.

The completeness of revenue recognition from medical treatment for inpatients.

The recognition of revenue on medical treatment for inpatients at the end of the year. The Company has recognized revenue by using the data from the resource base of the Company, which may result the accuracy and completeness of revenue recognition from medical treatment for inpatients.

I have assessment and testing of its systems and revenue recognition system and subsequent event testing for revenue on medical treatment for inpatients to ensure the revenue recognition from medical treatment of inpatients are properly recorded and complete.

Based on our testing, in my opinion, the revenues from medical treatment for inpatients are properly recorded and complete.

RY

Other Information

Management is responsible for the other information. The other information comprises the information included in annual report, but does not include the financial statements and my auditor's report thereon. The annual report is expected to be made available to me after the date of this auditor's report.

My opinion on the financial statements does not cover the other information and I do not express any form of assurance conclusion thereon.

In connection with my audit of the financial statements, my responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or my knowledge obtained in the audit or otherwise appears to be materially misstated.

When I read the annual report, if I conclude that there is a material misstatement therein, I am required to communicate the matter to those charged with governance for correction of the misstatement.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with Thai Financial Reporting Standards, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

My objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes my opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Thai Standards on Auditing will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with Thai Standards on Auditing, I exercise professional judgment and maintain professional skepticism throughout the audit. I also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for my opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

RY

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If I conclude that a material uncertainty exists, I am required to draw attention in my auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify my opinion. My conclusions are based on the audit evidence obtained up to the date of my auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

I communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that I identify during my audit.

I also provide those charged with governance with a statement that I have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on my independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, I determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. I describe these matters in my auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, I determine that a matter should not be communicated in my report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.



(Ms. Ratchneekon Vijaksilp)

Certified Public Accountant Registration No. 5801

Dr. Virach & Associates Office Co., Ltd.

Bangkok : February 8, 2024

NONTHAVEJ HOSPITAL PUBLIC COMPANY LIMITED

STATEMENTS OF FINANCIAL POSITION

AS AT DECEMBER 31, 2023

	Notes	BAHT	
		2023	2022
ASSETS			
Current Assets			
Cash and cash equivalents	3.2 and 4	902,187,624	975,945,597
Trade receivable	3.3 and 5	218,337,727	212,870,855
Inventories	3.4 and 6	57,041,236	61,893,544
Other current financial assets			
Investments in Open-ended Fund	3.3 and 7.1	32,384	37,769
Marketable securities	3.3 and 7.2	965,209	1,042,895
Total other current financial assets		997,593	1,080,664
Current portion of other non-current financial assets			
Other investment	3.3 and 8.2	100,000,000	100,000,000
Other current assets			
Prepaid expenses		24,897,812	22,911,707
Other current assets		4,475,891	3,267,243
Total other current assets		29,373,703	26,178,950
Total Current Assets		1,307,937,883	1,377,969,610
Non-current Assets			
Other non-current financial assets			
Marketable securities	3.3 and 8.1	10,224,600	15,376,700
Other investment	3.3 and 8.2	100,000,000	100,000,000
Fixed deposit at bank	3.3 and 8.3	300,000,000	-
Total other non-current financial assets		410,224,600	115,376,700
Property, plant and equipment	3.5 and 9	1,233,641,503	1,228,913,650
Intangible assets	3.6 and 10	21,680,140	26,702,463
Deferred tax assets	3.7 and 17	17,097,093	15,852,151
Other non-current assets	3.8 and 11	7,028,929	7,403,975
Total Non-current Assets		1,689,672,265	1,394,248,939
TOTAL ASSETS		2,997,610,148	2,772,218,549

RY

Notes to the financial statements form an integral part of these statements.

NONTHAVEJ HOSPITAL PUBLIC COMPANY LIMITED

STATEMENTS OF FINANCIAL POSITION

AS AT DECEMBER 31, 2023

LIABILITIES AND SHAREHOLDERS' EQUITY

	<u>Notes</u>	BAHT	
		2023	2022
Current Liabilities			
Trade and other current payables	12	212,581,381	209,333,174
Assets acquisition payable		21,504,402	11,164,096
Accrued corporate income tax		41,023,948	40,314,256
Other current liabilities		10,575,694	8,624,756
Total Current Liabilities		285,685,425	269,436,282
Non-current Liabilities			
Provision for long-term employee benefits	3.11 and 13	77,888,381	71,570,400
Total Non-current Liabilities		77,888,381	71,570,400
TOTAL LIABILITIES		363,573,806	341,006,682
Shareholders' Equity			
Share capital			
Authorized share capital			
160,000,000 common stocks of Baht 1 par value		160,000,000	160,000,000
Issued and paid-up share capital			
160,000,000 common stocks at Baht 1 each		160,000,000	160,000,000
Additional paid-in capital			
Premium on common stocks		172,000,000	172,000,000
Retained earnings			
Appropriated			
Legal reserve	14	16,000,000	16,000,000
Unappropriated		2,259,728,253	2,052,782,098
Other components of shareholders' equity		26,308,089	30,429,769
Total Shareholders' Equity		2,634,036,342	2,431,211,867
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY		2,997,610,148	2,772,218,549

RY

Notes to the financial statements form an integral part of these statements.

NONTHAVEJ HOSPITAL PUBLIC COMPANY LIMITED

STATEMENTS OF COMPREHENSIVE INCOME

FOR THE YEAR ENDED DECEMBER 31, 2023

	Notes	BAHT	
		2023	2022
REVENUES			
Revenues from medical treatment		2,471,547,730	2,255,305,762
Other income		13,185,741	14,825,412
Total Revenues		2,484,733,471	2,270,131,174
EXPENSES			
Cost of medical treatment		1,706,912,291	1,598,889,344
Selling expenses		5,375,539	4,098,539
Administrative expenses		301,930,710	283,988,650
Directors' remuneration	15	4,206,000	2,869,000
Total Expenses		2,018,424,540	1,889,845,533
Profit from operating activities		466,308,931	380,285,641
Finance income		11,692,405	4,539,652
Reversal (loss) on for expected credit		5,328,438	(9,696,742)
Unrealized loss on open-ended funds	3.3 and 7.1	(5,385)	(1,121)
Unrealized loss on marketable securities	3.3 and 7.2	(77,686)	(190,002)
Profit before Income Tax Expenses		483,246,703	374,937,428
Income Tax Expenses	3.9 and 17	(95,500,548)	(74,373,773)
Profit for the years		387,746,155	300,563,655
Other Comprehensive Income (Loss) :-			
Other comprehensive income not to be reclassified to profit or loss in subsequent periods			
Gain (loss) on changes in value of marketable securities			
Gain (loss) recognized in other comprehensive income	3.3 and 8.1	(5,152,100)	3,999,254
Income tax on net change from the remeasuring of marketable securities		1,030,420	(799,851)
Gain (loss) on changes in value of marketable securities-net of tax		(4,121,680)	3,199,403
Other comprehensive income (loss) for the years - net of tax		(4,121,680)	3,199,403
Total comprehensive income for the years		383,624,475	303,763,058
Earnings Per Share			
Basic Earnings Per Share	3.10	2.42	1.88

The number of 160,000,000 common stocks used in computation.

RY

NONTHAVEJ HOSPITAL PUBLIC COMPANY LIMITED
STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY
FOR THE YEAR ENDED DECEMBER 31, 2023

BAHT

	Notes	Retained earnings				Other components of shareholders' equity				Total shareholders' equity
		Issued and paid-up share capital	Premium on common stocks	Legal reserve	Unappropriated	Marketable securities	Actuarial gain from employee benefit plan	Total other components of shareholders' equity	Total	
Balances as at January 1, 2022		160,000,000	172,000,000	16,000,000	1,848,218,443	8,924,120	18,306,246	27,230,366	2,223,448,809	
Total comprehensive income for the year		-	-	-	300,563,655	3,199,403	-	3,199,403	303,763,058	
Dividend payment	15	-	-	-	(96,000,000)	-	-	-	(96,000,000)	
Balances as at December 31, 2022		160,000,000	172,000,000	16,000,000	2,052,782,098	12,123,523	18,306,246	30,429,769	2,431,211,867	
Total comprehensive income (loss) for the year		-	-	-	387,746,155	(4,121,680)	-	(4,121,680)	383,624,475	
Dividend payment	15	-	-	-	(180,800,000)	-	-	-	(180,800,000)	
Balances as at December 31, 2023		160,000,000	172,000,000	16,000,000	2,259,728,253	8,001,843	18,306,246	26,308,089	2,634,036,342	

RSY

NONTHAVEJ HOSPITAL PUBLIC COMPANY LIMITED

STATEMENTS OF CASH FLOWS

FOR THE YEAR ENDED DECEMBER 31, 2023

BAHT

	2023	2022
CASH FLOWS FROM OPERATING ACTIVITIES :		
PROFIT FOR THE YEAR	387,746,155	300,563,655
ADJUSTMENTS TO RECONCILE PROFIT FOR THE YEAR		
TO NET CASH PROVIDED FROM (USED IN) OPERATION :-		
Income tax expenses	95,500,548	74,373,773
Depreciation	166,750,394	174,880,522
Amortization of deferred expenses	4,424,203	3,765,094
Amortization of computer softwares	7,934,275	7,473,853
Unrealized loss on open-ended funds	5,385	1,121
Unrealized loss on marketable securities	77,686	190,002
Gain on disposal of equipment	(50,383)	(90,325)
Loss on unused of equipment	2,074,433	67,793
Bad debts	389,597	1,955,984
(Reversal) loss on for expected credit	(5,328,438)	9,696,742
Dividend income	(336,431)	(299,852)
Finance income	(11,692,405)	(4,539,652)
Long-term employee benefits expenses	12,450,415	11,125,036
PROFIT FROM OPERATION BEFORE CHANGE IN		
OPERATING ASSETS AND LIABILITIES ITEMS	659,945,434	579,163,746
(INCREASE) DECREASE IN OPERATING ASSETS ITEMS		
Trade receivables	(528,031)	(43,092,036)
Inventories	4,852,308	(3,683,044)
Other current assets	(1,612,530)	606,343
Other non-current assets	(4,049,157)	(5,994,035)
INCREASE (DECREASE) IN OPERATING LIABILITIES ITEMS		
Trade and other current payables	395,580	27,715,663
Assets acquisition payable	(9,186,205)	(28,373,096)
Other current liabilities	1,950,938	242,248
Provision for long-term employee benefits	(6,132,434)	(5,374,429)
Cash received from operation	645,635,903	521,211,360
Interest income	10,110,183	4,398,736
Income tax paid	(95,005,379)	(53,138,052)
NET CASH PROVIDED FROM OPERATING ACTIVITIES	560,740,707	472,472,044

RSY

Notes to the financial statements form an integral part of these statements.

NONTHAVEJ HOSPITAL PUBLIC COMPANY LIMITED

STATEMENTS OF CASH FLOWS (CONTINUED)

FOR THE YEAR ENDED DECEMBER 31, 2023

	BAHT	
	2023	2022
CASH FLOWS FROM INVESTING ACTIVITIES		
Increase in other non-current financial assets	(300,000,000)	(100,000,000)
Increase in plant and equipment	(152,287,219)	(93,406,077)
Proceeds from disposal of equipment	589,060	275,390
Increase in intangible assets	(2,336,952)	(1,315,850)
Proceeds from dividend income	336,431	299,852
NET CASH USED IN INVESTING ACTIVITIES	(453,698,680)	(194,146,685)
CASH FLOWS FROM FINANCING ACTIVITIES		
Dividend payment	(180,800,000)	(96,000,000)
NET CASH USED IN FINANCING ACTIVITIES	(180,800,000)	(96,000,000)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	(73,757,973)	182,325,359
CASH AND CASH EQUIVALENTS AS AT JANUARY 1,	975,945,597	793,620,238
CASH AND CASH EQUIVALENTS AS AT DECEMBER 31,	902,187,624	975,945,597
ADDITIONAL DISCLOSURE ITEMS TO CASH FLOWS STATEMENTS		
Non-cash flows items comprise :		
Unrealized gain (loss) on marketable securities	(5,152,100)	3,999,254
Increase in plant and equipment from assets acquisition payable	18,951,511	3,892,909
Increase in equipment from retention	2,852,627	2,426,799
Increase in intangible assets from assets acquisition payable	575,000	329,560
Increase in intangible assets from transferring fixed assets	-	256,000
Decrease in intangible assets and assets acquisition payable from changing in scope of work	-	(401,250)

RY

Notes to the financial statements form an integral part of these statements.

NONTHAVEJ HOSPITAL PUBLIC COMPANY LIMITED
NOTES TO THE FINANCIAL STATEMENTS
DECEMBER 31, 2023

1. GENERAL INFORMATION

1.1	Company status	A juristic person established under Thai law and listed on the Stock Exchange of Thailand.
1.2	Company location	432, Ngamvongwan Road, Tambol Bangkhen, Amphur Muangnonthaburi, Nonthaburi, Thailand.
	Branch	530, Rattanathibeth Road, Tambol Bangkrasor, Amphur Muangnonthaburi, Nonthaburi, Thailand.
1.3	Type of business	Hospital

2. BASIS FOR PREPARATION OF FINANCIAL STATEMENTS

2.1 The financial statements are prepared in accordance with the Accounting Standards and Financial Reporting Standards issued by Federation of Accounting Professions under the Accounting Profession Act, B.E. 2547 (2004), the Accounting Act, B.E. 2543 (2000) and the Notification of the Office of the Securities and Exchange Commission.

2.2 These financial statements have been prepared on a historical cost basis except where otherwise disclosed in the accounting policies.

2.3 Accounting standards that became effective in the current accounting year

During the year, the Company has adopted the revised financial reporting standards and interpretations which are effective for fiscal years beginning on or after 1 January 2023. These financial reporting standards were aimed at alignment with the corresponding International Financial Reporting Standards with most of the changes directed towards clarifying accounting treatment and, for some standards, providing temporary reliefs or temporary exemptions for users.

The adoption of these financial reporting standards does not have any significant impact on the Company's financial statements.

2.4 Financial reporting standards that will become effective for fiscal years beginning on or after January 1, 2024

The Federation of Accounting Professions issued a number of revised financial reporting standards, which are effective for fiscal years beginning on or after January 1, 2024. These financial reporting standards were aimed at alignment with the corresponding International Financial Reporting Standards with most of the changes directed towards clarifying accounting treatment and providing accounting guidance for users of the standards.

Management of the Company is evaluating the impact of such financial reporting standards on the financial statements in the year when they are adopted.

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

3.1 Revenues and expenses recognition

Revenues from hospital operations

Revenues from hospital operations, mainly consisting of medical fees, hospital room sales and medicine sales, are recognised as income when services have been rendered or medicine delivered.

Service income is recognized when services have been rendered.

Revenues from rental are recognized over the term of rental agreement.

Dividend income is recognized when the right to receive is established.

Other revenues and expenses are recognized on an accrual basis.

3.2 Cash and cash equivalents

Cash and cash equivalents are cash on hand and deposits at the financial institutions due not more than 3 months from the acquisition date and not subject to withdrawal restrictions.

3.3 Fair value measurement

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between buyer and seller (market participants) at the measurement date. The Company applies a quoted market price in an active market to measure their assets and liabilities that are required to be measured at fair value by relevant financial reporting standards. Except in case of no active market of an identical asset or liability or when a quoted market price is not available, the Company measures fair value using valuation technique that are appropriate in the circumstances and

maximizes the use of relevant observable inputs related to assets and liabilities that are required to be measured at fair value.

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorized within the fair value hierarchy into three levels based on categorize of input to be used in fair value measurement as follows :

Level 1 Use of quoted market prices in an active market for such assets or liabilities.

Level 2 Use of other observable inputs for such assets or liabilities, whether directly or indirectly.

Level 3 Use of unobservable inputs such as estimates of future cash flows.

At the end of each reporting period, the Company determines whether transfer have occurred between levels within the fair value hierarchy for assets and liabilities held at the end of the reporting period that are measured at fair value on a recurring basis.

The Company's financial instruments are measured as follows :

- Other current financial assets that are investments in Open-ended Fund are measured at fair value through profit or loss.
- Other current financial assets which is equity instruments-marketable securities are measured at fair value through profit or loss.
- Other non-current financial assets which is equity instruments-marketable securities are measured at fair value through other comprehensive income.
- Other non-current financial assets which is savings lottery are measured at amortised cost.

Impairment of financial assets

- The Company has applied a simplified approach to determine the lifetime expected credit loss for trade accounts receivable.

3.4 Inventories

Inventories are stated at cost or net realizable value, whichever is the lower. Cost is determined by the moving average method.

3.5 Property, plant and equipment

Property, plant and equipment are stated at cost. Depreciation is calculated by the straight-line method based on the estimated useful life of the following assets :

PARTICULARS	USEFUL LIFE (YEARS)
Land	No calculation for depreciation
Temporary building	3
Building and structure	10-50
Medical tools and equipment	5-10
Others	5-15

3.6 Intangible assets

Deferred computer software is stated at cost net from cumulative amortization which is calculated by the straight-line method within 5 years.

3.7 Deferred tax assets/liabilities

Deferred tax assets/liabilities are recognized for temporary differences arising between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes as at the statements of financial position date. They will be realised in future period when the income is realised, or the expenses provided for are actually incurred and considered deductible for income tax purposes.

Deferred tax assets are recognized for deductible temporary differences or addtible tax are deferred tax liabilities if it is highly probable that the Company will generate sufficient taxable profits from its future operations to utilise these assets/liabilities.

As each statements of financial position date, the Company reviews and adjusts the carrying amount of deferred tax assets/liabilities to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax assets or deferred tax liabilities to be utilised.

3.8 Deferred expenses

Deferred expenses are stated at cost net from cumulative amortization which is calculated by the straight-line method within 3-5 years.

3.9 Income tax expenses

Income tax expenses are calculated from profit/loss for the years consist of current tax and deferred tax. Income tax expenses recognized in statements of comprehensive income unless part of transaction recorded in shareholders' equity recorded directly to equity.

3.10 Earnings per share

Basic earnings per share is calculated by dividing the profit for the years by the number of weighted average common stocks held by outsiders during the years.

3.11 Employee benefits

Short-term employee benefits

Salaries, wages, bonuses and contributions to the social security fund are recognised as expenses when incurred.

Long-term employee benefits

Defined contribution plan

The Company provides a provident fund, which is a defined contribution plan. The assets of which are held in a separate trust fund and managed by the external fund manager. Such provident fund is contributed by payments from employees and the Company. Contributions to the provident fund are charged to the statements of comprehensive income in the incurred year.

Defined benefits plan

Provision for employee retirement benefits is recognised as an expense of operations over the employee's service period. It is calculated by estimating the amount of future benefit earned by employees in return for service provided to the Company in the current and future periods, with such benefit being discounted to determine the present value. The reference point for setting the discount rate is the yield rate of government bonds as at the reporting date. The calculation is performed by a qualified actuary using the Projected Unit Credit Method.

3.12 Significant accounting judgments and estimates

In preparation of financial statements in accordance with generally accepted accounting principles requires management to use judgment on various estimates and assumptions that will affect the reported amounts of revenues, expenses, assets and liabilities including the disclosure of contingent assets and liabilities. Actual results may differ from those estimates.

Estimates and assumptions are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. The Company makes estimates and assumptions

concerning the future. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions of significant accounting relate primarily to allowance for expected credit loss, depreciation of plant and equipment, amortization of intangible assets, amortization of deferred expenses and provision for long-term employee benefits. All other estimates mentioned above are further disclosed in the corresponding notes to the financial statements.

4. CASH AND CASH EQUIVALENTS

PARTICULARS	AMOUNT IN BAHT	
	2023	2022
Cash	1,671,675	1,896,592
Bank deposits	900,515,949	974,049,005
Total	902,187,624	975,945,597

5. TRADE RECEIVABLES

PARTICULARS	AMOUNT IN BAHT	
	2023	2022
The trade accounts receivable are classified by outstanding balances of aging as follows :		
Current	204,031,666	200,604,810
Overdue within 3 months	15,412,779	8,664,299
Over 3 - 6 months	936,020	3,421,493
Over 6 - 12 months	420,865	11,447,069
Over 12 months	14,078,507	10,603,732
Total	234,879,837	234,741,403
Allowance for expected credit loss	(16,542,110)	(21,870,548)
Total trade receivables - net	218,337,727	212,870,855

6. INVENTORIES

PARTICULARS	AMOUNT IN BAHT	
	2023	2022
Medicines and medical supplies	47,032,198	51,371,451
General supplies	10,009,038	10,522,093
Total	57,041,236	61,893,544

7. OTHER CURRENT FINANCIAL ASSETS**7.1 Open-ended fund**

PARTICULARS	AMOUNT IN BAHT	
	2023	2022
Open-ended fund	47,141	47,141
Valuation adjustment	(14,757)	(9,372)
Open-ended fund-Fair value	32,384	37,769

PARTICULARS	AMOUNT IN BAHT	
	2023	2022
Unrealized loss on open-ended fund	5,385	1,121

7.2 Marketable securities

PARTICULARS	AMOUNT IN BAHT	
	2023	2022
Acquisition cost	2,007,731	2,007,731
Valuation adjustment	(1,042,522)	(964,836)
Fair value at ending years	965,209	1,042,895

PARTICULARS	AMOUNT IN BAHT	
	2023	2022
Unrealized loss on marketable securities	77,686	190,002

8. OTHER-NON-CURRENT FINANCIAL ASSETS**8.1 Marketable securities**

PARTICULARS	AMOUNT IN BAHT	
	2023	2022
Acquisition cost	222,296	222,296
Valuation adjustment	10,002,304	15,154,404
Fair value at ending years	10,224,600	15,376,700

PARTICULARS	AMOUNT IN BAHT	
	2023	2022
Gain (loss) on changes in value of marketable securities	(5,152,100)	3,999,254

8.2 Other investment

PARTICULARS	AMOUNT IN BAHT	
	2023	2022
Savings lottery (due January 11, 2025 / January 8, 2023)	100,000,000	100,000,000
Savings lottery (due October 3, 2024)	100,000,000	100,000,000
Total	200,000,000	200,000,000
Current portion	(100,000,000)	(100,000,000)
Total	100,000,000	100,000,000

8.3 Fixed deposit at bank

PARTICULARS	AMOUNT IN BAHT
	2023
Fixed deposit at bank 24 months	300,000,000
Interest rate per annum	1.85 - 2.00
Accrued interest	266,027

10. INTANGIBLE ASSETS

PARTICULARS	AMOUNT IN BAHT		
	DEFERRED COMPUTER SOFTWARES	COMPUTER SOFTWARES UNDER INSTALLATION	TOTAL
<u>Cost</u>			
January 1, 2022	129,213,384	4,836,400	134,049,784
Increase for the year 2022	1,287,210	358,200	1,645,410
Transfer in (out)	4,435,150	(4,435,150)	-
Reduce from changing in scope of work	-	(401,250)	(401,250)
Transfer from fixed assets	256,000	-	256,000
December 31, 2022	135,191,744	358,200	135,549,944
Increase for the year 2023	1,698,552	1,213,400	2,911,952
December 31, 2023	136,890,296	1,571,600	138,461,896
<u>Accumulated amortization</u>			
January 1, 2022	101,373,628	-	101,373,628
Amortization for the year 2022	7,473,853	-	7,473,853
December 31, 2022	108,847,481	-	108,847,481
Amortization for the year 2023	7,934,275	-	7,934,275
December 31, 2023	116,781,756	-	116,781,756
<u>Net book value</u>			
December 31, 2022	26,344,263	358,200	26,702,463
December 31, 2023	20,108,540	1,571,600	21,680,140

11. OTHER NON-CURRENT ASSETS

PARTICULARS	AMOUNT IN BAHT	
	2023	2022
Deferred expenses	5,948,893	3,449,761
<u>Add</u> Increase	4,124,447	6,264,226
<u>Less</u> Amortization for the years	(4,424,203)	(3,765,094)
Net book value	5,649,137	5,948,893
Deposit for assets	1,379,792	1,371,792
Others	-	83,290
Total	7,028,929	7,403,975

12. TRADE AND OTHER CURRENT PAYABLES

PARTICULARS	AMOUNT IN BAHT	
	2023	2022
Trade accounts payables	59,905,656	62,940,575
Accrued expenses	46,236,043	33,152,470
Accrued doctors' fees	79,073,925	79,791,354
Others	27,365,757	33,448,775
Total	212,581,381	209,333,174

13. PROVISION FOR LONG-TERM EMPLOYEE BENEFITS

Provision for long-term employee benefits as at December 31, 2023 and 2022 which are compensations on employees' retirement, are as follows

PARTICULARS	AMOUNT IN BAHT	
	2023	2022
Defined benefit obligation at beginning of years	71,570,400	65,819,793
<u>Add</u> Current service cost	11,465,231	10,214,277
Interest cost	985,184	910,759
<u>Less</u> Benefits paid during the years	(6,132,434)	(5,374,429)
Defined benefit obligation at end of years	77,888,381	71,570,400

The key assumptions used in determining the employee benefits are shown as follows:

16. EXPENSES BY NATURE

EXPENSES	AMOUNT IN BAHT	
	2023	2022
Medicine and medical supply consumptions	450,205,123	446,831,909
Directors and management benefit expenses	15,379,650	13,381,000
Employee benefit expenses	588,569,716	523,532,970
Doctors' fees	566,652,738	529,786,807
Depreciation and amortization expenses	179,108,872	186,119,469
Bad debts	389,597	1,955,984

17. INCOME TAXES

Corporate income tax of the Company for the years ended December 31, 2023 and 2022 are calculated from the accounting profits and adjusted with other revenues and some expenses which are exempted from income tax or being disallowable expenses in corporate income tax computation.

The Company income taxes are calculated at the rate of 20 percent in 2023 and 2022.

Income tax expenses recognized in statements of comprehensive income consist:

FOR THE YEARS ENDED DECEMBER 31,	AMOUNT IN BAHT	
	2023	2022
Corporate income tax for the years	95,715,071	77,501,468
Amortization and reversal of temporary differences assets/liabilities on temporary differences	(214,523)	(3,127,695)
Income tax expenses	95,500,548	74,373,773

As at December 31, 2023 and 2022, the deferred tax assets/liabilities arose from the following temporary differences:

PARTICULARS	AMOUNT IN BAHT	
	2023	2022
Temporary differences in the statements of comprehensive income		
Allowance for adjustment investment value in Open-ended Fund	14,757	9,372
Allowance for adjustment in market securities		
- other current financial assets	1,042,522	964,836
Allowance for expected credit loss	16,542,110	21,870,548
Provision for long-term employees benefits	77,888,381	71,570,400
Total	95,487,770	94,415,156
Temporary differences in other comprehensive income		
- Recognized in other components of shareholders' equity		
Allowance for adjustment in market securities		
- other non-current financial assets	(10,002,304)	(15,154,404)
Total	85,485,466	79,260,752
Deferred tax assets calculated from tax rate of 20%	17,097,093	15,852,151

18. FINANCIAL INFORMATION BY SEGMENT

The Company is engaged in the business of medical treatment in one geographical area, Thailand. Therefore, the financial information by segment is not shown in these financial statements.

19. COMMITMENT

19.1 As at December 31, 2023 and 2022, the Company has commitment from the issuance of bank guarantee as follow :

PARTICULAR	AMOUNT IN BAHT	
	2023	2022
Letters of guarantee issued by commercial bank	4,276,800	4,276,800

19.2 Commitment under service agreement

As at December 31, 2023, the Company has entered into service agreements which can be cancelled when the counter party has prior notice 30 to 60 days in advance the amount of Baht 16.90 million.

19.3 Capital expenditure commitments

As at December 31, 2023, the Company has capital expenditure commitments to pay a total of Baht 34.04 million in regarding to the improvement of system and construction project.

20. PROVIDENT FUNDS

In compliance with the Provident Fund Act. B.E. 2530 (1987), the Company and its employees have jointly set up the provident fund which consists of partial contribution by its staff and another part by the Company as defined. The Company has appointed TISCO Asset Management Company Limited to be fund manager to manage this fund according to the Ministerial Regulations. The members are entitled to receive benefits according to the rules as stipulated.

Fund contribution from the Company is recorded as expenses in the statements of comprehensive income for the years ended December 31, 2023 and 2022 amount of Baht 5.77 million and Baht 4.99 million, respectively.

21. DISCLOSURE OF FINANCIAL INSTRUMENTS

The Company has information relating to financial instruments, as follows :

21.1 Accounting policies

- Accounting policies are disclosed in Note 3 to the financial statements.

21.2 Risk from breach of contracts

- The Company might have risk from breach of contract, in case the contracting party does not follow the requirement in the contract which may cause damage to the Company.
- The risk with respect to the concentration of credit arose from trade accounts receivable are limited due to the large number of customers and their dispersion.
- For the financial assets shown in the statements of financial position, the book value of such assets is net from various provisions to be estimated fair value. Such provisions are assumed to be the highest value of risk incurred from breach of contracts.

21.3 Risk relating to interest rate on financial assets and liabilities

Risk from the fluctuation in interest rate may have negative effect to the Company for the current and the following years. The Company expects that it can manage the contingent risk, due to the Company has set up a plan and follow up the situation closely.

21.4 Fair value of financial instruments

As at December 31, 2023 and 2022, the Company had the assets that were measured at fair value were disclosed using different levels of inputs as follows:

	BAHT			
	2023		2022	
	Level 1	Total	Level 1	Total
Assets measured at fair value				
Financial assets measured at fair value through profit or loss				
- Investment in Open-end Fund	32,384	32,384	37,769	37,769
- Marketable securities	965,209	965,209	1,042,895	1,042,895
- Other investment	200,000,000	200,000,000	200,000,000	200,000,000
Financial assets measured at fair value through other comprehensive income				
- Marketable securities	10,224,600	10,224,600	15,376,700	15,376,700

22. CAPITAL MANAGEMENT

The main objectives of the Company in capital management are to provide the appropriate financial structure and maintain ability to continue its business as a going concern in order to generate returns for shareholders and benefits for other stakeholders.

23. EVENTS AFTER THE REPORTING PERIOD

On February 8, 2024, the Board of Directors' Meeting No.1/2024 was held and approved a resolution to pay Annual Dividend to shareholders at Baht 1.46 per share totaling amount Baht 233.60 million. Such dividend will be proposed for approval in the next Ordinary General Shareholders' Meeting.

24. FINANCIAL STATEMENTS APPROVAL

These financial statements are duly approved by the Company's directors on February 8, 2024.